Cure8 research brief
People with IBD face an elevated lifetime risk of colitis-associated cancer; improved detection and risk prediction could lead to earlier treatment and better outcomes. AI could make surveillance more accurate and personalized, but current work is early-stage.
Clinicians doing endoscopic surveillance, researchers in AI and IBD, and patients interested in cancer-risk monitoring.
This narrative review summarizes evidence on machine learning (ML) and deep learning (DL) applied to detecting colitis-associated cancer (CAC) and predicting dysplasia risk in inflammatory bowel disease (IBD).
It focuses on how AI could improve lesion detection during surveillance, integrate multimodal data (clinical, endoscopic, histologic, molecular), and support personalized surveillance strategies.
The review reports that early studies are promising but limited; technical and clinical challenges remain, including data heterogeneity, need for large annotated datasets, and integration into clinical workflows. The authors highlight future directions toward precision medicine but do not present new clinical trial results.
If you follow advances in IBD surveillance, this paper outlines current AI approaches and the gaps that need to be addressed before widespread clinical use.
The source is a narrative review (abstract-level content). Findings summarize existing studies rather than reporting new clinical trial data; implementation challenges and need for validation are emphasized.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Next Generation EU-PNRR - NHS-PNRR-MAD- 2022-12375729
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
